A compound for use in a method for treatment of p38 mediated diseases or disorders, wherein the compound binds to the region composed of amino acids at positions 170 - 199 of SEQ ID NO.1 of MAPK14 (p38alpha) and/or SEQ ID NO.2 of MAPK11 (p38beta); and wherein the compound: is a peptide of up to 20 amino acids in length and which comprises a hexa-or heptapeptide having anyone of SEQ ID NO 3 or SEQ ID NO 6; or is a heterocylic compound of the following general formula: wherein R1 is NR2R3, or OR2; R2 is C5-C7-aryl or C5-C7-heteroaryl; wherein the C5-C7-aryl or C5-C7-heteroaryl, group is substituted with one or more of a -OR10, -SR10, -NHCOR10, -CONHR10, -COR10,-COOR10, -OCOR10, -NR10R11, -SO2R10, -SO2NR10R11 -CF3, -OCF3 or-CN, wherein R10 and R11 are independently of each other hydrogen, C1-C4-alkyl, C1-C4-alkenyl or C1-C4-alkynyl; and wherein if R1 is NR2R3, the C5-C7-aryl or C5-C7-heteroaryl, can be connected to the N via a single bond or NH; R3 is hydrogen or a C1-C4-alkyl group; R4---N---R6 is N=N-N or O-N=C; R5 is independently of each other N or CR11; wherein R11 is hydrogen, OH, or SH; R7 is an N-containing saturated or unsaturated C3-C7 heterocycloalkyl; L is a linker L, preferably a single covalent bond (so that R7 is linked directly to R8) or a C1 to C3 alkylen group, wherein one of the CH2 groups may be replaced by O, NH, or S; R8 is C5-C10-aryl or C5-C10-heteroaryl, which may be substituted at 4 position with a halogen, C1-C4 alky group, -OR12 or -SR12; wherein R12 is a C1 to C4 alkyl group; or a pharmaceutically acceptable salt, ester, and amide thereof; and wherein the p38 mediated diseases or disorders are selected from acute and/or chronic inflammatory diseases, macular degeneration, chronic pulmonary inflammatory disease and Alzheimer's disease. is a peptide of up to 20 amino acids in length and which comprises a hexa-or heptapeptide having anyone of SEQ ID NO 3 or SEQ ID NO 6; or is a heterocylic compound of the following general formula: wherein R1 is NR2R3, or OR2; R2 is C5-C7-aryl or C5-C7-heteroaryl; wherein the C5-C7-aryl or C5-C7-heteroaryl, group is substituted with one or more of a -OR10, -SR10, -NHCOR10, -CONHR10, -COR10,-COOR10, -OCOR10, -NR10R11, -SO2R10, -SO2NR10R11 -CF3, -OCF3 or-CN, wherein R10 and R11 are independently of each other hydrogen, C1-C4-alkyl, C1-C4-alkenyl or C1-C4-alkynyl; and wherein if R1 is NR2R3, the C5-C7-aryl or C5-C7-heteroaryl, can be connected to the N via a single bond or NH; R3 is hydrogen or a C1-C4-alkyl group; R4---N---R6 is N=N-N or O-N=C; R5 is independently of each other N or CR11; wherein R11 is hydrogen, OH, or SH; R7 is an N-containing saturated or unsaturated C3-C7 heterocycloalkyl; L is a linker L, preferably a single covalent bond (so that R7 is linked directly to R8) or a C1 to C3 alkylen group, wherein one of the CH2 groups may be replaced by O, NH, or S; R8 is C5-C10-aryl or C5-C10-heteroaryl, which may be substituted at 4 position with a halogen, C1-C4 alky group, -OR12 or -SR12; wherein R12 is a C1 to C4 alkyl group; or a pharmaceutically acceptable salt, ester, and amide thereof; and wherein the p38 mediated diseases or disorders are selected from acute and/or chronic inflammatory diseases, macular degeneration, chronic pulmonary inflammatory disease and Alzheimer's disease. R1 is NR2R3, or OR2; R2 is C5-C7-aryl or C5-C7-heteroaryl; wherein the C5-C7-aryl or C5-C7-heteroaryl, group is substituted with one or more of a -OR10, -SR10, -NHCOR10, -CONHR10, -COR10,-COOR10, -OCOR10, -NR10R11, -SO2R10, -SO2NR10R11 -CF3, -OCF3 or-CN, wherein R10 and R11 are independently of each other hydrogen, C1-C4-alkyl, C1-C4-alkenyl or C1-C4-alkynyl; and wherein if R1 is NR2R3, the C5-C7-aryl or C5-C7-heteroaryl, can be connected to the N via a single bond or NH; R3 is hydrogen or a C1-C4-alkyl group; R4---N---R6 is N=N-N or O-N=C; R5 is independently of each other N or CR11; wherein R11 is hydrogen, OH, or SH; R7 is an N-containing saturated or unsaturated C3-C7 heterocycloalkyl; L is a linker L, preferably a single covalent bond (so that R7 is linked directly to R8) or a C1 to C3 alkylen group, wherein one of the CH2 groups may be replaced by O, NH, or S; R8 is C5-C10-aryl or C5-C10-heteroaryl, which may be substituted at 4 position with a halogen, C1-C4 alky group, -OR12 or -SR12; wherein R12 is a C1 to C4 alkyl group; or a pharmaceutically acceptable salt, ester, and amide thereof; and wherein the p38 mediated diseases or disorders are selected from acute and/or chronic inflammatory diseases, macular degeneration, chronic pulmonary inflammatory disease and Alzheimer's disease.